#USA #San Diego #Evofem Biosciences #SOLOSEC #PHEXXI

Evofem Biosciences Reports Financials for Q3 2025

San Diego, CA — November 13, 2025
Evofem Biosciences, Inc. (OTCID: EVFM), a company dedicated to women's health, revealed its financial performance for the third quarter of 2025, marking a significant recovery period.

In a remarkable turnaround, Evofem reported net sales of $5.0 million, reflecting a 10% increase compared to Q3 2024’s $4.5 million. Saundra Pelletier, CEO of Evofem, attributed this success to the concerted efforts of the sales team and impactful social media marketing strategies that complemented favorable press coverage received in the summer.

Key Financial Highlights:

• - Net Sales: Increased to $5.0 million for Q3 2025, boosted by sales of PHEXX® and a full quarter of SOLOSEC® revenue.
• - Operating Income: The company turned around from a loss of $2.4 million in the prior year to achieve an operating income of $1.0 million in Q3 2025.
• - Cost Reductions: Operating expenses saw a major decrease of 42%, falling from $6.9 million in Q3 2024 to $4.0 million. This decrease was primarily due to reduced general and administrative costs alongside a one-time gain resulting from an accounting estimate adjustment related to the Rush royalty liability.

Product Development and Market Expansion:
Evofem is making strides in reducing the cost of goods sold (COGS) by approximately 50% for its products: PHEXX® (a hormone-free contraceptive) and SOLOSEC® (an antibiotic used for treating bacterial vaginosis and trichomoniasis). The reduced manufacturing costs are expected to facilitate entry into more price-sensitive global markets.
In line with this strategy, the marketing approval submission for SOLOSEC® was made in the United Arab Emirates during Q3. Furthermore, patient recruitment is ongoing for a Phase 4 clinical trial funded by the NIH to evaluate SOLOSEC®’s effectiveness compared to a traditional multi-dose treatment.

Challenges and Future Directions:
Despite these positive developments, Evofem faced hurdles earlier this year when their proposed merger with Aditxt did not receive shareholder approval in October. Consequently, Evofem exercised its right to terminate the merger agreement, shifting its focus back to its core operations and product lines.

Market Outlook:
Evofem’s leadership remains optimistic about the direction of the company. The recent financial outcomes and ongoing product advancements indicate a robust potential for growth within the women’s health sector. The focus remains steadfast on addressing unmet needs in women's sexual and reproductive health through innovative treatments.

About Evofem:
Evofem Biosciences is committed to developing and commercializing products that cater to women's sexual and reproductive health challenges. The company's flagship products, PHEXX® and SOLOSEC®, are FDA-approved and designed to provide effective solutions for common issues faced by women. Visit phexxi.com and solosec.com to learn more about their offerings.

As Evofem continues onward, stakeholders are keenly watching how its strategies take shape in the face of a changing business landscape, ensuring that women's health remains a priority in innovative healthcare solutions.